| Market Capitalization (Millions $) |
67 |
| Shares
Outstanding (Millions) |
61 |
| Employees |
8 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-57 |
| Cash Flow (TTM) (Millions $) |
-3 |
| Capital Exp. (TTM) (Millions $) |
0 |
Pyxis Oncology Inc
Pyxis Oncology Inc is a clinical-stage biopharmaceutical company which is focused on developing innovative cancer therapies. The company was founded in 2017 and is headquartered in Cambridge, Massachusetts.
Pyxis Oncology has a unique approach to cancer therapy, using a proprietary platform to identify and validate novel therapeutic targets. The platform is designed to identify targets that are important for tumor growth and survival, but are not currently targeted by existing therapies. This enables Pyxis to develop drugs that have the potential to be more effective and better tolerated than existing cancer treatments.
At the core of Pyxis Oncology's platform is a cutting-edge technology called Mass Spec. Mass Spec is a powerful tool that allows the company to identify thousands of proteins in tumor cells and compare them to normal cells. This enables Pyxis to identify proteins that are unique to cancer cells and target them with therapies that have a high specificity and low toxicity.
Pyxis Oncology's lead drug candidate is PYX-202, which is a monoclonal antibody targeting a protein called OX40. OX40 is a key regulator of T-cell function and has been shown to be important for tumor growth and survival. PYX-202 is currently in Phase I clinical trials for the treatment of advanced solid tumors.
In addition to PYX-202, Pyxis Oncology has a pipeline of other drug candidates targeting novel therapeutic targets. These include drugs targeting proteins such as CD73, CD39, and PSMA.
Pyxis Oncology has a world-class team of scientists and clinicians who have extensive experience in oncology drug development. The company has also built strong partnerships with leading academic institutions and pharmaceutical companies to accelerate the development of its drug candidates.
Overall, Pyxis Oncology is a promising biopharmaceutical company that is working to develop innovative cancer therapies that have the potential to make a significant impact on the lives of cancer patients.
Company Address: 321 Harrison Avenue Boston 2118 MA
Company Phone Number: 221-9059 Stock Exchange / Ticker: NASDAQ PYXS
|
